BR112018070586A8 - Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos - Google Patents

Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos

Info

Publication number
BR112018070586A8
BR112018070586A8 BR112018070586A BR112018070586A BR112018070586A8 BR 112018070586 A8 BR112018070586 A8 BR 112018070586A8 BR 112018070586 A BR112018070586 A BR 112018070586A BR 112018070586 A BR112018070586 A BR 112018070586A BR 112018070586 A8 BR112018070586 A8 BR 112018070586A8
Authority
BR
Brazil
Prior art keywords
compounds
pyrazol
treatment
medical disorders
carboxamide compounds
Prior art date
Application number
BR112018070586A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018070586A2 (pt
Inventor
T Skerlj Renato
Marie Josée Bourque Elyse
T Lansbury Peter
C Good Andrew
Original Assignee
Lysosomal Therapeutics Inc
Bial Biotech Invest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lysosomal Therapeutics Inc, Bial Biotech Invest Inc filed Critical Lysosomal Therapeutics Inc
Publication of BR112018070586A2 publication Critical patent/BR112018070586A2/pt
Publication of BR112018070586A8 publication Critical patent/BR112018070586A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112018070586A 2016-04-06 2017-04-06 Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos BR112018070586A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318929P 2016-04-06 2016-04-06
PCT/US2017/026280 WO2017176960A1 (en) 2016-04-06 2017-04-06 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

Publications (2)

Publication Number Publication Date
BR112018070586A2 BR112018070586A2 (pt) 2019-02-05
BR112018070586A8 true BR112018070586A8 (pt) 2023-03-14

Family

ID=60001526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070586A BR112018070586A8 (pt) 2016-04-06 2017-04-06 Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos

Country Status (12)

Country Link
US (4) US11192892B2 (https=)
EP (1) EP3440080A4 (https=)
JP (1) JP7038063B2 (https=)
KR (2) KR20180133461A (https=)
CN (1) CN109311887B (https=)
AU (1) AU2017246455B2 (https=)
BR (1) BR112018070586A8 (https=)
CA (1) CA3020287A1 (https=)
IL (1) IL262177B (https=)
MX (1) MX2018012211A (https=)
SG (1) SG11201808830YA (https=)
WO (1) WO2017176960A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
CA3020305A1 (en) * 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
SG11201809693SA (en) 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
CN110698484B (zh) * 2019-06-05 2021-11-05 陕西理工大学 含吡唑并[1,5-a]嘧啶的衍生物、药用组合物及应用
CN115108972A (zh) * 2022-08-29 2022-09-27 北京迪泰医药科技有限公司 一种2-甲基-3-氟-5-溴吡啶的合成方法
WO2025014639A2 (en) * 2023-07-07 2025-01-16 The Johns Hopkins University Neutral sphingomyelinase inhibitors
WO2025146216A1 (zh) * 2024-01-05 2025-07-10 成都赜灵生物医药科技有限公司 六并五氮杂环酰胺类化合物及其用途
CN118184599A (zh) * 2024-02-29 2024-06-14 重庆药友制药有限责任公司 一种阿莫奈韦中间体的制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
JP3763997B2 (ja) 1999-05-13 2006-04-05 富士写真フイルム株式会社 感熱記録材料
JP4331823B2 (ja) 1999-05-21 2009-09-16 富士フイルム株式会社 ピロロ［１，２−ａ］−１，３，５−トリアジン−４−オン系化合物
WO2001051919A2 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
JP4070966B2 (ja) 2001-06-28 2008-04-02 株式会社カネボウ化粧品 新規ガラクトシルセラミド類縁体及び用途
ATE307812T1 (de) 2001-10-22 2005-11-15 Pfizer Imidazopyridinverbindungen als 5-ht4- rezeptormodulatoren
US20050096322A1 (en) 2002-03-01 2005-05-05 Susumu Igarashi Nitrogen-containing heterocyclic compound
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
MXPA05003065A (es) 2002-09-20 2005-05-27 Pfizer Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4.
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
MXPA05011270A (es) 2003-04-21 2006-01-24 Pfizer Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3.
EP1682504B1 (en) 2003-11-12 2012-12-26 Amicus Therapeutics Inc. Hydroxy piperidine derivatives to treat gaucher disease
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AU2005212096B2 (en) 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
NZ551424A (en) 2004-05-14 2009-10-30 Childrenaes Cancer Inst Austra Small molecule inhibitors for MRP1 and other multidrug transporters
HRP20080070T3 (en) * 2004-06-21 2008-05-31 F. Hoffmann - La Roche Ag Pyrrazolo-pyrimidine derivatives
JP2008508337A (ja) 2004-08-02 2008-03-21 シュバルツ ファルマ アクチェンゲゼルシャフト インドリジンカルボキサミド並びにそのアザ及びジアザ誘導体
DE102004049363A1 (de) 2004-10-08 2006-04-13 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
WO2006078676A2 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN101115755B (zh) * 2005-02-11 2013-01-16 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
JPWO2006115168A1 (ja) 2005-04-21 2008-12-18 大日本住友製薬株式会社 Ｎ−置換フェニルアセトアミド誘導体およびそれを含有する医薬組成物
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CN101316847A (zh) 2005-10-06 2008-12-03 先灵公司 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
CN101296699B (zh) * 2005-10-21 2013-01-02 田边三菱制药株式会社 吡唑并[1,5-a]嘧啶化合物
CA2626789A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
AU2006322187A1 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
JP5303458B2 (ja) 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
AU2007321923A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20080255153A1 (en) 2007-03-28 2008-10-16 Biovitrum Ab (Publ) New compounds
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
WO2008157575A1 (en) 2007-06-21 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
MX2010005950A (es) 2007-11-28 2010-06-17 Schering Corp 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
WO2009119088A1 (ja) 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
TW201217312A (en) 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
DK2649075T3 (en) 2010-12-08 2018-07-30 Us Health SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012129258A1 (en) 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
CN103857657B (zh) 2011-08-18 2016-04-20 日本新药株式会社 杂环衍生物及医药
CN104039784B (zh) 2011-09-02 2017-08-22 拜耳知识产权有限责任公司 取代的增环嘧啶及其用途
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
RU2014120166A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
DK2822555T3 (en) 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
WO2013148333A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
KR20150020228A (ko) 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 아미노퀴나졸린 및 피리도피리미딘 유도체
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
WO2014025651A1 (en) 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
EA201590482A1 (ru) 2012-09-05 2015-07-30 Байер Кропсайенс Аг Применение замещенных 2-амидобензимидазолов, 2-амидобензоксазолов и 2-амидобензотиазолов или их солей в качестве биологически активных веществ против абиотического стресса растений
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
WO2014085607A1 (en) 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
KR20140086002A (ko) 2012-12-28 2014-07-08 한미약품 주식회사 Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체
US9963452B2 (en) 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3035921A1 (en) 2013-08-20 2016-06-29 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
AR097543A1 (es) 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
WO2015073267A1 (en) * 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
CN108290894A (zh) 2015-07-01 2018-07-17 西北大学 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
WO2017040877A1 (en) 2015-09-04 2017-03-09 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
US10479793B2 (en) 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
EP3416967B1 (en) 2016-02-18 2022-02-09 F. Hoffmann-La Roche AG Therapeutic compounds, compositions and methods of use thereof
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
EP3452045A1 (en) 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
SG11201809693SA (en) 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192929A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
JP2021506920A (ja) 2017-12-21 2021-02-22 リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用

Also Published As

Publication number Publication date
KR20180133461A (ko) 2018-12-14
US20230098494A1 (en) 2023-03-30
EP3440080A1 (en) 2019-02-13
US10934298B2 (en) 2021-03-02
CN109311887B (zh) 2022-09-13
US9840510B1 (en) 2017-12-12
BR112018070586A2 (pt) 2019-02-05
CN109311887A (zh) 2019-02-05
AU2017246455B2 (en) 2021-09-30
WO2017176960A1 (en) 2017-10-12
US20200017507A1 (en) 2020-01-16
JP7038063B2 (ja) 2022-03-17
IL262177B (en) 2022-06-01
AU2017246455A1 (en) 2018-10-25
EP3440080A4 (en) 2020-01-22
RU2018138688A3 (https=) 2020-08-31
US20170349598A1 (en) 2017-12-07
US11192892B2 (en) 2021-12-07
US20190330213A1 (en) 2019-10-31
KR20230104752A (ko) 2023-07-10
SG11201808830YA (en) 2018-11-29
IL262177A (en) 2018-11-29
JP2019510790A (ja) 2019-04-18
MX2018012211A (es) 2019-03-28
KR20230104752A9 (ko) 2024-11-15
CA3020287A1 (en) 2017-10-12
RU2018138688A (ru) 2020-05-19
US12116369B2 (en) 2024-10-15

Similar Documents

Publication Publication Date Title
BR112018070586A8 (pt) Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
BR112018072552A8 (pt) Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
MX394094B (es) PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
MX2018012208A (es) Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
MX388912B (es) Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
WO2010068483A3 (en) Mlk inhibitors and methods of use
BR112017010141A2 (pt) Forma cristalina de hidrogenossulfato de (s)-n-(5- ((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5- a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
MX368162B (es) Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
BR112018017067A2 (pt) pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
PH12022551223A1 (en) Adenosine receptor antagonist compounds
BR112019008604A2 (pt) compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
BR112019008163A2 (pt) compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
EP3881849C0 (en) COMPOSITION COMPRISING AN APTAMER AS AN ACTIVE INGREDIENT FOR THE TREATMENT AND PREVENTION OF A DEGENERATIVE BRAIN DISEASE
BR112019016815A2 (pt) tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas
BR0112619A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, métodos para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e de distúrbios no sistema nervoso central e/ou de bexiga hiperativa ou vasospasmo ou para o controle do crescimento de tumores
BR112019007954A2 (pt) inibidor da aldosterona sintase
MX383514B (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
BR112022006501A2 (pt) Composto que tem atividade inibitória de brd4, método de preparação do mesmo e uso do mesmo
EA201991062A1 (ru) Пиразоло[3,4-b]пиридины и имидазо[1,5-b]пиридазины в качестве ингибиторов pde1
HK40004413A (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIAL - BIOTECH INVESTMENTS, INC. (US)

B25G Requested change of headquarter approved

Owner name: BIAL - BIOTECH INVESTMENTS, INC. (US)

B25A Requested transfer of rights approved

Owner name: BIAL - RANDD INVESTMENTS, S.A. (PT)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.